Nascent Pharma Holdings Inc (NASC)

[sleekscape]

It looks like I severely underestimated CANB’s Q4 2018 revenue

I had projected $170,000 and CANB reported a whopping $283,000 for Q4 2018:

For a gain of 74% over Q3 2018 ($163,000)

For a gain of more than 300% over Q4 2017 ($62,000)

CBD product revenue was up over 700% for the full year 2018 ($650,000) compared to full year 2017 ($79,000)

And these Q4 results are purely from the Canbiola CBD line

SAM revenue (we will see this in Q1) and Pure Leaf Oil revenue (we will see this in Q2) are not included in the $283,000 Q4 2018 revenue

I’m going to review the rest of the annual report now

Here were some of my thoughts heading into the 2018 annual report:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147891979

I had been very excited about where CANB is heading in 2019 in terms of revenue growth, and this really helps to cement my optimism

Really looking forward to seeing Q1 results

Sleek